Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

http://www.wikidata.org/entity/Q34634002

about

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA The evolution of poxvirus vaccines Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein Experience of using an open source clinical trials data management software system in Kenya.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Targeting regulatory T cells to improve vaccine immunogenicity in early life.Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.Clinical applications of attenuated MVA poxvirus strain.Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls.Recombinant modified vaccinia virus Ankara-based malaria vaccines.Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.Development of replication-deficient adenovirus malaria vaccines.Malaria vaccines: past, present and future.Interferon-γ responses to Plasmodium falciparum vaccine candidate antigens decrease in the absence of malaria transmission.Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.

P2860

Q24289279-EEB20AC5-391A-4F44-AB9C-29FB816F76F4 Q26995905-BDD9667D-1859-4152-9CB4-25FEF9EA4BA0 Q27973488-FB0A9FEF-D27B-4620-99F3-5A391D15D3DB Q30872007-41C08DF7-577F-4FAE-AC5E-3C2941283F35 Q33577093-6C504BB0-4897-4430-9AD0-574C3AF4DEA1 Q33868760-C1EFAA95-532D-4C19-8EE9-4EAAD035FCF3 Q33875160-382788D7-3463-4F79-9247-C0652633941E Q34164169-3351B728-C699-416E-9CED-7C1DE8F9E4C2 Q34165879-FFAD6E08-96D6-4577-B3D5-01E6D6FB8017 Q34301461-9D14C60F-42D5-49AF-9B4C-CFB69B442610 Q34729962-1906D8B9-C9A5-4839-872E-2176F70E0C28 Q34734075-D775018A-C73C-4FC4-A7B8-EB0C5C1CFD65 Q35220369-56345B3B-F11D-4A0C-BE48-6AE056D7388B Q35344875-2C5863FE-AA9A-4593-BE2B-07F986DE142B Q36225504-816C2B51-31CC-4002-BC4A-A5023006ECA4 Q36393102-933E43CE-B7EE-4D8E-A21C-D9C52E148DB8 Q37161928-AA6E0086-A5BD-4D29-9352-1DDB3CF7F979 Q37229742-8F589342-1815-4E91-8E19-45ADBC6EC38D Q37353525-EB5D8B88-9515-4313-B339-2EFF372ED025 Q37641378-C6C0FB24-9DDD-457C-94C3-BDE7A7D780E7 Q38156198-91F40F77-10A1-4917-A74D-FAF0C3914B8F Q38295771-11238F88-6FA7-4595-A538-A543A500D56B Q38618898-5BDC821F-FC5B-41F1-81D0-AABC8F157933 Q38762695-6AD205B6-317F-4FB5-94A6-683FA31F1A5D Q38949194-D97A40AE-1BFD-4082-AA2D-23FFC5478CB8 Q39345614-47DAA72D-343C-4FD9-AEEB-15DDF5405DC7 Q40368142-DC4DDDDE-5E3A-4107-A271-A528FA3E3126 Q42003390-21B97382-166B-4EC7-AD82-0CE7D40C2390 Q46796163-4EC4B680-303D-4171-ADC0-91487E8ED9C2 Q50347547-7F4FFB89-D7A8-436D-B8FB-F18A11B6F451 Q53702329-95BBA575-E6C6-4283-B8C4-F76C9532C885

P2860

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

http://www.wikidata.org/entity/Q34634002

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@ast

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@en

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@nl

type

label

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@ast

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@en

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@nl

prefLabel

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@ast

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@en

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@nl

P1433

Q34634002-7460428E-BB4F-4141-9EF1-01AB55AED97F

P1476

Q34634002-22A70C3D-25FD-4081-A7CF-2C24D0AE1E21

P2093

Q34634002-052EE9E5-BACE-4717-8B38-60051D7C9C7D

Q34634002-16CCA4CD-6103-41C0-B101-99A8594ECA98

Q34634002-19EC00A9-4C48-4A9B-8315-433C00FFD40E

Q34634002-27204EB5-658E-4617-93EF-E02253946840

Q34634002-27F56E07-5EDC-4404-931A-A0F1DEF23337

Q34634002-2D932957-A099-4366-B3C8-E52D7FD12169

Q34634002-341B1174-5F2F-42BD-862C-3848E17B23D1

Q34634002-497AA9F9-372F-468D-B8F1-A4E1FDF93A6F

Q34634002-56150299-B153-4041-B697-86D22070815B

Q34634002-5DB612C8-6431-4CAD-951A-A252BE1EAF15

P2860

Q34634002-01655AD8-0280-4D65-8847-118D1D422AC1

Q34634002-0590CBC5-3734-4E5A-BC97-4F0DD0C1B2FB

Q34634002-093B7649-1398-4BCF-83B5-D2DD5CC119F6

Q34634002-098157B1-793D-4664-B336-B3FD4D796ACD

Q34634002-10EE6829-07BD-4829-9557-790C60F34F44

Q34634002-12EB9161-9666-4DBE-AD97-6106B942DA38

Q34634002-14429230-1163-4274-8245-25532AC3A76C

Q34634002-14A13E6B-A4DE-4886-97F5-44E95C17E941

Q34634002-282F2B18-7312-4E48-98F2-DBB3D7014563

Q34634002-3620FD2E-321D-4AD8-9E92-0903D956755E

P304

Q34634002-B28C99FC-1DAA-4288-864F-E1604BBDAD98

P31

Q34634002-162E929B-D746-4F1C-85C3-E8C92A3A10F8

P356

Q34634002-7494D415-FB55-49C1-8C9E-010AECB7E9D9

P407

Q34634002-F8CEE093-45C0-4711-A483-61426319A1C1

P433

Q34634002-8E6B2BCB-119F-4F0F-8BEB-0C1C67528657

P478

Q34634002-361F9725-904D-4304-9D6E-E1106CC117E6

P50

Q34634002-00C6C5D1-F8DB-45D3-9220-A407CC3A042A

Q34634002-048733F8-38DE-4C15-BBC9-AA52B9D47939

Q34634002-10D87188-5502-4A77-969C-75FF21FD7DB8

Q34634002-1345FEE9-FDAA-454D-8288-7ABB7E776199

Q34634002-1AB5F7B3-222E-49D2-BF2B-5A0CE366234D

Q34634002-4008B992-EAEF-456A-9061-7A65C68FCC72

Q34634002-654B2757-3AF3-4DFD-B4A9-DBBB942A75DE

Q34634002-9EB858D9-748F-4B5C-9537-6253D70AA1B0

Q34634002-C1BD04D8-AE12-4104-B8B3-C5AE1DA205CC

Q34634002-CEB45CF9-1244-4C7F-AF17-4C01D97BB8CB

P577

Q34634002-A502876C-0F8D-4FA1-8786-608B7B8D2A91

P5875

Q34634002-1DDAF186-AD30-4BDC-9A7B-DA54B9FFF64B

P698

Q34634002-4A830256-0ACA-4BB6-83EF-B70DF9945CAD

P921

Q34634002-44E1E7AE-7FE7-43A1-9713-67550320AD16

Q34634002-B43C481D-6E63-43E5-BC01-4C75A14E7F32

Q34634002-D60F4533-3E09-4228-A0B4-ABCA0BD5E36F

Q34634002-DFDFAD54-CAB5-4304-8F42-0DC6082FB790

P932

Q34634002-C3B18053-13C1-42AB-85E4-60899655B36C

P356

JOURNAL.PONE.0057726

P1433

P1476

Safety and immunogenicity of h ...... lthy Gambian and Kenyan adults

@en

P2093

Alfredo Nicosia

http://www.w3.org/2001/XMLSchema#string

Alison M Lawrie

http://www.w3.org/2001/XMLSchema#string

Carly M Bliss

http://www.w3.org/2001/XMLSchema#string

Christopher J A Duncan

http://www.w3.org/2001/XMLSchema#string

Domtila Kimani

http://www.w3.org/2001/XMLSchema#string

Eleanor Berrie

http://www.w3.org/2001/XMLSchema#string

Eva Kimani

http://www.w3.org/2001/XMLSchema#string

Jenny Mueller

http://www.w3.org/2001/XMLSchema#string

Katherine Gantlett

http://www.w3.org/2001/XMLSchema#string

Katie J Ewer

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines against malaria

Global malaria mortality between 1980 and 2010: a systematic analysis

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Continued decline of malaria in The Gambia with implications for elimination.

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.

P304

e57726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0057726

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Adrian V. S. Hill

Sarah Catherine Gilbert

Egeruan B Imoukhuede

Kalifa A Bojang

Alexandra Spencer

Katharine A Collins

Muhammed Afolabi

P577

2013-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236078757

http://www.w3.org/2001/XMLSchema#string

P698

23526949

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

3602521

http://www.w3.org/2001/XMLSchema#string